NavigAID for Immuno-Oncology

Protagen is expanding its NavigAID offering to support the development of immunotherapeutic anticancer drugs, owing to the role played by autoantibodies in cancer as well as autoimmune disease.

Protagen’s NavigAID tools are already enabling disease stratification and response prediction for chronic and debilitating autoimmune diseases by measuring autoantibody levels in serum. Based on this success, and the inherent role played by autoantibodies in cancer as well as autoimmune diseases, Protagen is expanding its NavigAID offering to support the development of immunotherapeutic anticancer drugs.

Protagen’s research has shown that autoantibodies can be used as biomarkers for the onset of immune-related adverse events (irAEs), as well as predictors of overall survival for cancer patients undergoing immunotherapy. Together with its collaborative partners, Protagen is harnessing SeroTag® to develop NavigAID tools for the profiling of autoantibodies that will enable the stratification of patients based on factors such as their disease profile, likely treatment response or incidence of irAEs.

The detection of autoantibody signatures in various cancers will enable the field to better predict immunotherapy response, and disease stratification will support the future development of safe and effective immunotherapies. As autoantibodies have already been shown to be powerful indicators of irAE incidence and therapeutic response, developing NavigAID panels for their detection will help the field of immuno-oncology to answer its most pressing questions.

If you would like to learn more about how these tools can help in the successful development of more effective, safer therapies, contact us now.

Immuno-Oncology

Protagen is dedicated to the development of precision medicine tools that are giving pharmaceutical and biotech companies the power to develop safer anti-cancer drugs, and enabling clinicians to select the right therapy for the right patient.

Immuno-Oncology Applications

Protagen is able to detect autoantibodies for the prediction and monitoring of immune-related adverse events (irAEs), as well as therapeutic response for patients undergoing cancer immunotherapy.

SeroTag® Platform

SeroTag® is Protagen’s proprietary biomarker discovery engine, which is used to discover and validate novel biomarkers that can help stratify different cancer indications and autoimmune diseases.

Get in touch

Improving the treatment of cancer and autoimmune disease is our passion, and we always welcome the chance to discuss these topics with current and prospective customers, patients and clinicians alike.

We sometimes like to share the latest industry insights and company news, would you like to be added to our database?

15 + 8 =

Copyright © 1997-2018
Protagen AGDortmund, Germany